Search the Newsreel

Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations

This article provides analyst insights, price targets, and recommendations for Cytek Biosciences, Inc. (8EQ.MU). It lists several recent analyst actions including upgrades, downgrades, and maintained ratings from firms like Piper Sandler, Goldman Sachs, Stephens & Co., and Morgan Stanley, along with the corresponding dates. …

Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A

Millennium-affiliated entities and Israel A. Englander have filed an amended Schedule 13G/A, disclosing significant ownership stakes in Cytek Biosciences, Inc. Integrated Core Strategies (US) LLC reported a 5.5% beneficial ownership, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported …

Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary

Cytek Biosciences, Inc. reported its second-quarter 2026 results, showing a 5.6% year-over-year revenue increase to $48.14 million, alongside a net loss of $12.16 million and diluted EPS of ($0.09). Revenue growth was fueled by product and service gains, with improved gross margin attributed to …

Cytek Biosciences, Inc. (CTKB) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Cytek Biosciences, Inc. (CTKB), including its current stock price, recent news, historical data, and financial analysis. The company specializes in cell analysis solutions for biomedical research and clinical applications, offering various instruments and reagents. The …

Cytek Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CTKB) 2026-08-06

Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates

Cytek Biosciences Reports Second Quarter 2026 Financial Results

Cytek Biosciences reported its second-quarter 2026 financial results, with total revenue reaching $48.1 million, a 6% increase year-over-year. The company also announced the launch of new instruments, the Cytek Borealis™ and updated Cytek Aurora™ Evo configurations, and updated its full-year 2026 revenue guidance to …

Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...

Cytek Biosciences (CTKB) reported a 6% year-over-year revenue increase to $48.1 million in Q2 2026, driven by strong growth in the US and China, particularly from high-end instrument sales and services. Despite this, the company saw a widened GAAP net loss of $12.2 million …

Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million

Cytek Biosciences reported its Q2 2026 financial results, showing a 6% year-over-year increase in revenue to $48.1 million. Despite the revenue growth, the company's GAAP net loss widened to $12.2 million, and its GAAP operating loss increased to $11.4 million. The gross margin improved …

Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1 million, a 5.6% increase year-over-year, and gross profit rose by 18.7% to $28.3 million. Despite revenue growth, the company posted a net loss of $12.2 million, or $(0.09) diluted EPS, missing analyst expectations of $(0.0867) …

Cytek Q2 2026 Earnings: Revenue Rose 6% as Losses Widened

Cytek (Nasdaq: CTKB) reported a 6% increase in Q2 2026 revenue to $48.1 million, driven by instrument growth in the U.S. and China and higher service revenue. However, the company's net losses widened significantly due to a faster increase in operating expenses and weaker …

Cytek Biosciences GAAP EPS of -$0.09 in-line, revenue of $48.1M misses by $0.51M

* Cytek Biosciences press release [https://seekingalpha.com/pr/20608750-cytek-biosciences-reports-second-quarter-2026-financial-results] (CTKB [https://seekingalpha.com/symbol/CTKB]): Q2 GAAP EPS of -$0.09 in-line. * Revenue of $48.1M (+5.5% Y/Y) misses by $0.51M. * GAAP gross profit was $28.3 million for the second quarter of 2026, a 19% increase compared to the second quarter …

Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall

Cytek Biosciences reported a 6% increase in second-quarter 2026 revenue to $48.1 million, driven by strong demand in the U.S. and China, but also announced a wider net loss and negative adjusted EBITDA. Despite raising the low end of its full-year revenue guidance, shares …

Cytek Biosciences (CTKB) Earnings Date and Reports 2026

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates

Boston Partners (CTKB) discloses 7.64M-share beneficial stake in Cytek Biosciences

Boston Partners has reported a beneficial ownership of 7,635,145 shares of Cytek Biosciences, Inc. (CTKB) common stock, which represents a 5.91% stake in the company as of June 30, 2026. This disclosure was made via a Schedule 13G SEC filing, indicating that Boston Partners …

Cytek Biosciences Inc (CTKB) Institutional Confidence

This article analyzes the institutional confidence score for Cytek Biosciences Inc (CTKB), which stands at 5.00, ranking 107th in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 65.16%, a decrease of 8.01% quarter-over-quarter. Bill Nygren (OAKMX) is the largest institutional shareholder …

Cytek Biosciences Inc (CTKB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cytek Biosciences Inc (CTKB), detailing its price momentum, support and resistance levels, and various technical indicators. It highlights that the stock is currently trading between resistance at $4.75 and support at $4.21, suggesting a range-bound swing trading …

Cytek Biosciences (CTKB) Expected to Release Quarterly Earnings on Wednesday

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for

Cytek Biosciences Inc (CTKB) Risk Assessment: Volatility, Financial Risk & Investment Risk

Cytek Biosciences Inc (CTKB) has a current risk assessment score of 4.63, placing it 98th out of 199 in the Healthcare Equipment & Supplies industry. The stock exhibits a beta value of 1.19, indicating higher volatility compared to the S&P 500. The assessment also …

Cytek Biosciences, Inc. Revenue Breakdown – TRADEGATE:8EQ

Cytek Biosciences, Inc. (8EQ) generated ‪171.55 million EUR in revenue last year, with its Full Spectrum Flow Cytometry Platform segment contributing the most at ‪122.80 million EUR. The United States was the largest regional contributor, accounting for ‪81.10 million EUR. This represents an increase …

Cytek Biosciences Inc (CTKB) Cash Flow

This article provides a detailed overview of Cytek Biosciences Inc.'s (CTKB) cash flow statement, including operating, investing, and financing activities. It presents quarterly and annual financial figures, showing fluctuations and year-over-year changes in net income, capital expenditures, and free cash flow. The article also …

Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cytek Biosciences Inc (CTKB) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page displays current stock information including its price, market cap, …

Cytek Biosciences Inc (CTKB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cytek Biosciences Inc (CTKB), listing its major institutional holders and their respective proportions. It also categorizes shareholders by type, such as Investment Advisors and Hedge Funds, and provides a historical overview of institutional shareholding changes across different …

Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Cytek Biosciences Inc (CTKB) for Fiscal Year 2023. It categorizes revenue by business segments, namely "Biotechnology, pharmaceutical, distributor and CRO" and "Academia and government," and also by geographical regions including the United States, EMEA, APAC, and …

Cytek Biosciences (CTKB) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Shares Slip - ROE Trend Analysis

CTKB|Cytek Biosciences Inc|Price:4.460|Chg%:-0.100

This article provides a comprehensive overview of Cytek Biosciences Inc (CTKB), including its current stock price, market performance, key financial figures, and analyst ratings. The company, which specializes in cell analysis solutions, is highlighted for its healthy fundamentals and significant growth potential, although its …

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?

This article analyzes Champions Oncology, Inc. (CSBR) and Cytek Biosciences, Inc. (CTKB), two life sciences companies, to determine which offers better long-term upside. It compares their stock performance, valuation, and factors driving their respective businesses, concluding that CSBR presents a more favorable entry point …

CTKB stock rises as Cytek BioSciences reports revenue and margin trends

Cytek BioSciences (CTKB) stock is being evaluated based on its reported revenue and margin trends, driven by its flow cytometry platform and recurring demand from its installed base. The article emphasizes that revenue, margin, and cash generation are key indicators, especially focusing on the …

Cytek Biosciences sets Q2 results call for 4:30 p.m. ET Aug. 5

Cytek Biosciences (Nasdaq: CTKB) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a webcast conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments and outlook. …

Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Cytek Biosciences (NASDAQ: CTKB) announced it will release its second quarter 2026 financial results on August 5, 2026, after market close. The company will also host a conference call and webcast to discuss these results and provide a business update. A replay of the …

Cytek Biosciences Opens Bellevue Innovation Center to Advance R&D and Customer Engagement

Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating its Seattle-area operations to enhance research and development, collaboration, and customer engagement. The facility integrates R&D laboratories, training areas, and assembly operations, signifying Cytek's strategic investment in advancing high-dimensional cell analysis. This …